$8.24
0.243%
Last update: Oct 30, 6:43 PM
Akari Therapeutics PLC (AKTX) Stock Price, Quote, News & History
AKTXNASDAQ
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
You can purchase shares of Akari Therapeutics (NASDAQ:AKTX) through any online brokerage.
Other companies in Akari Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Akari Therapeutics has a consensus price target of $32.33.
The stock price for Akari Therapeutics (NASDAQ: AKTX) is $8 last updated October 30, 2026 at 6:43 PM EDT.
There are no upcoming dividends for Akari Therapeutics.
Akari Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Akari Therapeutics.
Akari Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the...
